Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Bioorthogonal Iontronic Chemistry: Spatiotemporal Drug Release with Electronic Precision

Project description

Biontronic chemistry-based innovative drug delivery system

Drug delivery is often ineffective and side effects are common. Combining local drug delivery with chronotherapy could significantly enhance treatment efficacy and reduce or eliminate side effects. The ERC-funded Time2SWITCH project aims to develop a new drug delivery system based on biontronic chemistry. This technology integrates bioorthogonal release chemistry and iontronic devices allowing for precise and controlled drug release at the target site. The project plans to create a system that offers unprecedented opportunities for therapies such as cancer treatment, nerve regeneration and aging. The overarching goal is to achieve drug delivery with electronic precision—ensuring the right drugs are delivered at the right place and at the right time—ultimately transforming the way medicines are administered and unlocking new possibilities in therapeutic interventions.

Objective

I envision a new drug delivery system capable spatiotemporal release with electronic precision.
This technology is based on; Biontronic Chemistry (BC) which combines Bioorthogonal Release (BR) and Iontronic transport to overcome the drawbacks of each individual technology and combine their unique advantages. An electronic ion pump (IP) will enable programable electrophoretic transport of chemical triggers without liquid flow or moving mechanical parts to initiate the ultrafast & selective bioorthogonal release (BR) of drugs at the target site to generate previously unobtainable dynamic concentration-time profiles. Hence, BC translates electrical stimuli, of arbitrary frequencies and amplitudes, into tailor-made bio-chemical concentration/time profiles. By incorporating surface release functionalities and orthogonal bioorthogonal chemistries I will further expand the concept and demonstrate choreographed cascade releases to afford individually programmable release of multiple compounds with distinct concentration/time profiles. We will map out this large parameter space using a combination of rational chemical design, computationally aided device physics and engineering, fluorescent model systems and finally evaluation in cell models. T2S will lay the foundation for new directions in science and offer unprecedented opportunities for various therapies wherein choreographed, spatiotemporal control of multiple drug release is key (e.g. cancer; nerve regeneration and aging). My hypothesis is that if we combine local drug delivery and chronotherapy, we can dramatically increase treatment efficacy and reduce (if not completely) eliminate side effects. My overarching goal is to create a Switch that elevates medicine to the 5th dimension (5D) thus paving the way towards a paradigm shift in drug delivery and our understanding/ability to manipulate biological-spacetime by delivering the right dose (1D) at the right place (3D) at the right time (1D).

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-STG

See all projects funded under this call

Host institution

TECHNISCHE UNIVERSITAET WIEN
Net EU contribution
€ 1 496 795,00
Address
KARLSPLATZ 13
1040 Wien
Austria
Region
Ostösterreich Wien Wien
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 496 795,00

Beneficiaries (1)